Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Pan Canadian Pharmaceutical Alliance
Deal Size : Undisclosed
Deal Type : Agreement
Details : Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.
Product Name : Allerject
Product Type : Hormone
Upfront Cash : Undisclosed
October 08, 2020
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Pan Canadian Pharmaceutical Alliance
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved FDF
Sponsor : Optinose
Deal Size : Undisclosed
Deal Type : Agreement
Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
Details : Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.
Product Name : Xhance
Product Type : Steroid
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved FDF
Sponsor : Optinose
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
